HRP20171570T1 - Tapentadol za sprječavanje i liječenje depresije i tjeskobe - Google Patents
Tapentadol za sprječavanje i liječenje depresije i tjeskobe Download PDFInfo
- Publication number
- HRP20171570T1 HRP20171570T1 HRP20171570TT HRP20171570T HRP20171570T1 HR P20171570 T1 HRP20171570 T1 HR P20171570T1 HR P20171570T T HRP20171570T T HR P20171570TT HR P20171570 T HRP20171570 T HR P20171570T HR P20171570 T1 HRP20171570 T1 HR P20171570T1
- Authority
- HR
- Croatia
- Prior art keywords
- tapentadol
- use according
- anxiety
- depression
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11003508 | 2011-04-29 | ||
| EP12720794.2A EP2701693B1 (en) | 2011-04-29 | 2012-04-27 | Tapentadol for preventing and treating depression and anxiety |
| PCT/EP2012/001819 WO2012146383A1 (en) | 2011-04-29 | 2012-04-27 | Tapentadol for preventing and treating depression and anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171570T1 true HRP20171570T1 (hr) | 2017-11-17 |
Family
ID=44260882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171570TT HRP20171570T1 (hr) | 2011-04-29 | 2012-04-27 | Tapentadol za sprječavanje i liječenje depresije i tjeskobe |
| HRP20200600TT HRP20200600T1 (hr) | 2011-04-29 | 2020-04-15 | Tapentadol za sprječavanje i liječenje depresije i tjeskobe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200600TT HRP20200600T1 (hr) | 2011-04-29 | 2020-04-15 | Tapentadol za sprječavanje i liječenje depresije i tjeskobe |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120277319A1 (enExample) |
| EP (3) | EP2701693B1 (enExample) |
| JP (3) | JP6014655B2 (enExample) |
| CY (2) | CY1119586T1 (enExample) |
| DK (2) | DK3272343T3 (enExample) |
| ES (2) | ES2788548T3 (enExample) |
| HR (2) | HRP20171570T1 (enExample) |
| HU (2) | HUE049308T2 (enExample) |
| LT (2) | LT2701693T (enExample) |
| NO (1) | NO2701693T3 (enExample) |
| PL (2) | PL3272343T3 (enExample) |
| PT (2) | PT2701693T (enExample) |
| RS (2) | RS56523B1 (enExample) |
| SI (2) | SI2701693T1 (enExample) |
| WO (1) | WO2012146383A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| ES2428938T3 (es) | 2009-07-22 | 2013-11-12 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación |
| CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| PL2736497T3 (pl) | 2011-07-29 | 2018-01-31 | Gruenenthal Gmbh | Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| PT3302454T (pt) * | 2015-05-26 | 2021-04-01 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Composições para utilização no tratamento da doença de parkinson e distúrbios associados |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US10292948B2 (en) * | 2017-01-11 | 2019-05-21 | Torrent Pharmaceuticals Limited | Tapentadol nasal composition |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| CA2620364A1 (en) | 2005-08-26 | 2007-03-01 | David C. Yeomans | Methods for treatment of headaches by administration of oxytocin |
| US20090306050A1 (en) | 2006-02-03 | 2009-12-10 | Timothy Dinan | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
| PL2012763T3 (pl) | 2006-04-28 | 2011-08-31 | Gruenenthal Gmbh | Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID |
| DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| CN102065852B (zh) | 2007-11-23 | 2015-06-17 | 格吕伦塔尔有限公司 | 他喷他多组合物 |
| US20100297181A1 (en) | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| WO2010100477A2 (en) | 2009-03-03 | 2010-09-10 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| MX2011011442A (es) | 2009-04-30 | 2011-11-18 | Gruenenthal Gmbh | Uso de compuestos de 1-fenil-3-dimetilaminopropano para tratar dolor reumatoide. |
| FR2970261B1 (fr) | 2011-01-10 | 2013-05-03 | IFP Energies Nouvelles | Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive |
| EP2694049B1 (en) | 2011-04-05 | 2018-10-31 | Grünenthal GmbH | Tapentadol for preventing chronification of pain |
-
2012
- 2012-04-27 NO NO12720794A patent/NO2701693T3/no unknown
- 2012-04-27 EP EP12720794.2A patent/EP2701693B1/en active Active
- 2012-04-27 WO PCT/EP2012/001819 patent/WO2012146383A1/en not_active Ceased
- 2012-04-27 HU HUE17185830A patent/HUE049308T2/hu unknown
- 2012-04-27 PT PT127207942T patent/PT2701693T/pt unknown
- 2012-04-27 EP EP19218383.8A patent/EP3656380A1/en not_active Withdrawn
- 2012-04-27 US US13/458,510 patent/US20120277319A1/en not_active Abandoned
- 2012-04-27 HU HUE12720794A patent/HUE034003T2/en unknown
- 2012-04-27 SI SI201231099T patent/SI2701693T1/sl unknown
- 2012-04-27 ES ES17185830T patent/ES2788548T3/es active Active
- 2012-04-27 PL PL17185830T patent/PL3272343T3/pl unknown
- 2012-04-27 RS RS20171076A patent/RS56523B1/sr unknown
- 2012-04-27 RS RS20200431A patent/RS60152B1/sr unknown
- 2012-04-27 HR HRP20171570TT patent/HRP20171570T1/hr unknown
- 2012-04-27 DK DK17185830.1T patent/DK3272343T3/da active
- 2012-04-27 JP JP2014506793A patent/JP6014655B2/ja not_active Expired - Fee Related
- 2012-04-27 LT LTEP12720794.2T patent/LT2701693T/lt unknown
- 2012-04-27 LT LTEP17185830.1T patent/LT3272343T/lt unknown
- 2012-04-27 PL PL12720794T patent/PL2701693T3/pl unknown
- 2012-04-27 ES ES12720794.2T patent/ES2646363T3/es active Active
- 2012-04-27 DK DK12720794.2T patent/DK2701693T3/da active
- 2012-04-27 EP EP17185830.1A patent/EP3272343B1/en active Active
- 2012-04-27 PT PT171858301T patent/PT3272343T/pt unknown
- 2012-04-27 SI SI201231768T patent/SI3272343T1/sl unknown
-
2014
- 2014-09-30 US US14/502,552 patent/US20150018426A1/en not_active Abandoned
-
2016
- 2016-09-20 JP JP2016183088A patent/JP2017031182A/ja active Pending
-
2017
- 2017-03-27 US US15/470,385 patent/US9980927B2/en active Active
- 2017-08-29 JP JP2017163838A patent/JP6445637B2/ja not_active Expired - Fee Related
- 2017-11-10 CY CY20171101178T patent/CY1119586T1/el unknown
-
2020
- 2020-04-15 HR HRP20200600TT patent/HRP20200600T1/hr unknown
- 2020-04-16 CY CY20201100360T patent/CY1123051T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| EP2396073A4 (en) | IONTOPHORETIC SYSTEM FOR THE TRANSDERMAL ACTIVE SUBSTANCE FOR THERAPEUTIC AND MEDICAL USE | |
| JP2015523407A5 (enExample) | ||
| JP2013505282A5 (enExample) | ||
| MX371432B (es) | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. | |
| JP2015515475A5 (enExample) | ||
| JP2016053040A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| PH12014502331A1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2012502915A5 (enExample) | ||
| WO2011159100A3 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| JP2013516493A5 (enExample) | ||
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| PH12014502836B1 (en) | Medicament form for release of active ingredients | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| WO2012085249A3 (en) | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid | |
| WO2011161223A3 (en) | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts | |
| JP2015516451A5 (enExample) | ||
| IN2012CH05549A (enExample) | ||
| HRP20160811T1 (hr) | Upotreba odiparcila u liječenju mukopolisaharidoze | |
| WO2019203759A3 (en) | Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation. | |
| HRP20230105T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti |